Clear All
760 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
HCPCS Generic Name Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class Oral (Y/N) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
NA Entrectinib Rozlytrek 100mg, 200mg Chemotherapy Tyrosine Kinase Inhibitor TRKA, TRKB, TRKC, ROS1, ALK Yes 2019 In Use
NA Bromocriptine Mesylate Parlodel Chemotherapy Dopamine Agonist Ergot Derivative Yes 1978 In Use
NA tretinoin Vesanoid 10 mg Hormonal Therapy Immunomodulator Retinoic Acid Derivative Yes 1995 In Use
NA Finasteride Proscar 5mg Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Yes 1992 In Use
NA Mitotane Lysodren unspecified Chemotherapy Miscellaneous Agent Adrenal Suppressant Yes 1970 In Use
NA Aprepitant Emend 40 mg Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Yes 2003 In Use
NA Alectinib Alecensa 150 mg Chemotherapy Tyrosine Kinase Inhibitor ALK Yes 2015 In Use
NA Midostaurin Rydapt 25 mg Chemotherapy Tyrosine Kinase Inhibitor FLT3 Yes 2017 In Use
NA Relugolix Orgovyx 120mg Hormonal Therapy Androgen Receptor Inhibitor GnRH Receptor Antagonist Yes 2020 In Use
NA Cyclosporine Sandimmune 25mg, 50mg, 100mg Ancillary Therapy Immunomodulator Calcineurin Inhibitor Yes 1983 In Use
NA Afatinib Gliotrif 20 mg Chemotherapy Tyrosine Kinase Inhibitor EGFR Yes 2013 In Use
NA Flutamide Euflex, Eulexin 125 mg Hormonal Therapy Androgen Receptor Inhibitor Yes 1989 In Use
NA Niraparib Zejula 100 mg Chemotherapy Enzyme Inhibitor PARP Yes 2017 In Use
NA olaparib Lynparza 50 mg Chemotherapy Enzyme Inhibitor PARP Yes 2014 In Use
NA Cabozantinib Cometriq 20 mg Chemotherapy Tyrosine Kinase Inhibitor VEGFR Yes 2012 In Use
NA Nilutamide Anadron, Nilandron 150 mg Hormonal Therapy Androgen Receptor Inhibitor Yes 1996 In Use
NA Rucaparib Rubraca 300 mg Chemotherapy Enzyme Inhibitor PARP Yes 2017 In Use
N/A Ensartinib ENSACOVE 25mg, 100mg Chemotherapy Tyrosine Kinase Inhibitor ALK, ROS1, MET Yes 2025 In Use
N/A Taletrectinib IBTROZI 272mg Chemotherapy Tyrosine Kinase Inhibitor ROS1, TRKA, TRKB, TRKC Yes 2025 In Use
N/A Avutometinib potassium and defactinib hydrochloride AVMAPKI FAKZYNJA CO-PACK 0.8mg and 200mg Chemotherapy MEK Inhibitor, Tyrosine Kinase Inhibitor MEK1/2, ERK1/2, KRAS Yes 2025 In Use
J9999 Chemotherapy - non specific Not otherwise classified, antineoplastic drugs NA Chemotherapy No In Use
J9600 Porfimer Photofrin 75 mg Chemotherapy Photosensitizing Agent Cytotoxin No 1995 Jan 1, 1998 In Use
J9400 Ziv-aflibercept Zaltrap 1 mg Chemotherapy Recombinant Fusion Protein VEGF-IgG1 No 2012 Jan 1, 2014 In Use
J9395 Fulvestrant Faslodex 25 mg Hormonal Therapy Estrogen Receptor Antagonist No 2002 Jan 1, 2004 In Use
J9394 Fulvestrant (Fresnius) Fulvestrant (Fresnius) 25mg Hormonal Therapy Estrogen Receptor Antagonist No 2019 Dec 21, 2022 In Use
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.